Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Aug;9(8):1691-7.
doi: 10.4161/hv.24873. Epub 2013 Jun 6.

Concomitant administration of hepatitis A vaccine with measles/mumps/rubella/varicella and pneumococcal vaccines in healthy 12- to 23-month-old children

Robert J Yetman  1 , Julie S Shepard, Anton Duke, Jon E Stek, Maria Petrecz, Stephanie O Klopfer, Barbara J Kuter, Florian P Schödel, Andrew W Lee
Affiliations
Randomized Controlled Trial

Concomitant administration of hepatitis A vaccine with measles/mumps/rubella/varicella and pneumococcal vaccines in healthy 12- to 23-month-old children

Robert J Yetman et al. Hum Vaccin Immunother. 2013 Aug.

Abstract

This open-label, multicenter, randomized, comparative study evaluated immunogenicity, safety and tolerability of concomitant (Group 1; n=330) vs. non-concomitant (Group 2; n=323) VAQTA™ (25U/0.5 mL) (hepatitis A vaccine; HAV) with ProQuad™ (measles/mumps/rubella/varicella; MMRV) and Prevnar™ (7-valent pneumococcal; PCV-7) in healthy, 12-23 mo old children. Group 1 received HAV/MMRV/PCV-7 concomitantly on Day 1 and second doses of HAV/MMRV at Week 24. Group 2 received MMRV/PCV-7 on Day 1, HAV at Weeks 6 and 30 and MMRV at Week 34. Hepatitis A seropositivity rate (SPR: ≥10 mIU/mL; 4 weeks postdose 2), varicella zoster-virus (VZV) SPR (≥5 gpELISA units/mL) and geometric mean titers (GMT) to S. pneumoniae were examined. Injection-site and systemic adverse experiences (AEs) and daily temperatures were collected. Hepatitis A SPR were 100% for Group 1 and 99.4% for Group 2 after two HAV doses; risk difference=0.7 (95%CI: -1.4,3.8, non-inferior) regardless of initial serostatus. VZV SPR was 93.3% for Group 1 and 98.3% for Group 2; risk difference=-5.1 (95%CI: -9.3, -1.4; non-inferior). S. pneumoniae GMT fold-difference (7 serotypes) ranged from 0.9 to 1.1; non-inferior. No statistically significant differences in the incidence of individual AEs were seen when HAV was administered concomitantly vs. non-concomitantly. Three (all Group 2 post-administration of MMRV/PCV-7) of 11 serious AEs were considered possibly vaccine-related: dehydration and gastroenteritis (same subject) on Day 52; febrile seizure on Day 9. No deaths were reported. Antibody responses to each vaccine given concomitantly were non-inferior to HAV given non-concomitantly with MMRV and PCV-7. Administration of HAV with PCV-7 and MMRV had an acceptable safety profile in 12- to 23-mo-old children.

Trial registration: ClinicalTrials.gov NCT00312858.

Keywords: concomitant use; hepatitis A; immunogenicity; measles; mumps; pneumococcal; rubella; safety; vaccine; varicella.

PubMed Disclaimer

Figures

None
Figure 1. Subject accounting.
See this image and copyright information in PMC

References

    1. U.S. Package Circular. VAQTA™ (Hepatitis A Vaccine, Inactivated): February 2003. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedPro.... Accessed: 03-Apr-2013.
    1. Fiore AE, Wasley A, Bell BP, Advisory Committee on Immunization Practices (ACIP) Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep. 2006;55(RR07):1–23. - PubMed
    1. Werzberger A, Kuter B, Shouval D, Mensch B, Brown L, Wiens B, et al. Anatomy of a trial: a historical view of the Monroe inactivated hepatitis A protective efficacy trial. J Hepatol. 1993;18(Suppl 2):S46–50. doi: 10.1016/S0168-8278(05)80378-2. - DOI - PubMed
    1. Linglöf T, van Hattum J, Kaplan KM, Corrigan J, Duval I, Jensen E, et al. An open study of subcutaneous administration of inactivated hepatitis A vaccine (VAQTA) in adults: safety, tolerability, and immunogenicity. Vaccine. 2001;19:3968–71. doi: 10.1016/S0264-410X(01)00134-7. - DOI - PubMed
    1. Hornick R, Tucker R, Kaplan KM, Eves KA, Banerjee D, Jensen E, et al. A randomized study of a flexible booster dosing regimen of VAQTA in adults: safety, tolerability, and immunogenicity. Vaccine. 2001;19:4727–31. doi: 10.1016/S0264-410X(01)00224-9. - DOI - PubMed

Publication types

MeSH terms

Substances

Associated data